Literature DB >> 2960833

Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein.

T M Varsanyi1, B Morein, A Löve, E Norrby.   

Abstract

The importance of each of the two surface glycoproteins of measles virus in active and passive immunization was examined in mice. Infected-cell lysates were depleted of either the hemagglutinin (H) or fusion (F) glycoprotein by using multiple cycles of immunoaffinity chromatography. The products were used to prepare immune-stimulating complexes (iscoms) containing either F or H glycoprotein. Such complexes are highly immunogenic, possibly as a result of effective presentation of viral proteins to the immune system [B. Morein, B. Sundquist, S. Höglund, K. Dalsgaard, and A. Osterhaus, Nature (London) 308:457-460, 1984]. Groups of 3-week-old BALB/c mice were inoculated with the iscom preparations. All animals developed hemolysis-inhibiting antibodies, whereas only sera of animals immunized with the iscoms containing the H glycoprotein had hemagglutination-inhibiting antibodies. Sera from animals immunized with the H or F preparation only precipitated the homologous glycoprotein in radioimmune precipitation assays. The immunized animals were challenged with a lethal dose of the hamster neurotropic variant of measles virus. Of the 7-week-old animals in the nonimmunized control group, 50% died within 10 days after challenge. No animals in the immunized groups showed symptoms of disease throughout the observation period of 3 months. Passive administration of anti-H monoclonal antibodies gave full protection against the 100% lethal acute infection with the hamster neurotropic variant of measles virus in newborn mice, whereas anti-F monoclonal antibodies failed to protect the animals. This study emphasizes that both H and F glycoproteins need to be considered in the development of measles virus subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960833      PMCID: PMC256008     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  THE DEVELOPMENT OF A NEUROTROPIC STRAIN OF MEASLES VIRUS IN HAMSTERS AND MICE.

Authors:  T BURNSTEIN; J H JENSEN; B H WAKSMAN
Journal:  J Infect Dis       Date:  1964-06       Impact factor: 5.226

2.  Characterization of epitopes on the measles virus hemagglutinin.

Authors:  H Sheshberadaran; E Norrby
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

3.  Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

4.  Trypsin action on the growth of Sendai virus in tissue culture cells. 3. Structural difference of Sendai viruses grown in eggs and tissue culture cells.

Authors:  M Homma; M Ouchi
Journal:  J Virol       Date:  1973-12       Impact factor: 5.103

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

7.  Age dependence of viral expression: comparative pathogenesis of two rodent-adapted strains of measles virus in mice.

Authors:  D E Griffin; J Mullinix; O Narayan; R T Johnson
Journal:  Infect Immun       Date:  1974-04       Impact factor: 3.441

8.  Purification, morphology and antigenic characterization of measles virus envelope components.

Authors:  T M Varsanyi; G Utter; E Norrby
Journal:  J Gen Virol       Date:  1984-02       Impact factor: 3.891

9.  Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines.

Authors:  V A Fulginiti; J J Eller; A W Downie; C H Kempe
Journal:  JAMA       Date:  1967-12-18       Impact factor: 56.272

10.  Protection against canine distemper virus in dogs after immunization with isolated fusion protein.

Authors:  E Norrby; G Utter; C Orvell; M J Appel
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

View more
  11 in total

1.  An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration.

Authors:  K Lövgren; H Kåberg; B Morein
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge.

Authors:  E Malvoisin; F Wild
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins.

Authors:  Paulo H Verardi; Fatema H Aziz; Shabbir Ahmad; Leslie A Jones; Berhanu Beyene; Rosemary N Ngotho; Henry M Wamwayi; Mebratu G Yesus; Berhe G Egziabher; Tilahun D Yilma
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity.

Authors:  F Bouche; W Ammerlaan; F Berthet; S Houard; F Schneider; C P Muller
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

5.  Neutralizing human Fab fragments against measles virus recovered by phage display.

Authors:  Cristina de Carvalho Nicacio; R Anthony Williamson; Paul W H I Parren; Ake Lundkvist; Dennis R Burton; Ewa Björling
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection.

Authors:  C B Stephensen; J Welter; S R Thaker; J Taylor; J Tartaglia; E Paoletti
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

7.  Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein.

Authors:  R S van Binnendijk; J P Versteeg-van Oosten; M C Poelen; H F Brugghe; P Hoogerhout; A D Osterhaus; F G Uytdehaag
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Immunological responses of mice and cattle to baculovirus-expressed F and H proteins of rinderpest virus: lack of protection in the presence of neutralizing antibody.

Authors:  M Bassiri; S Ahmad; L Giavedoni; L Jones; J T Saliki; C Mebus; T Yilma
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions.

Authors:  L Giavedoni; L Jones; C Mebus; T Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

10.  Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge.

Authors:  J Taylor; S Pincus; J Tartaglia; C Richardson; G Alkhatib; D Briedis; M Appel; E Norton; E Paoletti
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.